

Original Research Article

The effect of *Capsella bursa-pastoris* extract on Heavy Menstrual Bleeding and quality of life in patients with uterine leiomyoma; a double-blind randomized clinical trial

Abstract

Objectives: Heavy Menstrual Bleeding (HMB) is the most important problems of Uterine Leiomyoma (UL). This study aimed to assess the effect of the extract of the *Capsella bursa-pastoris* (CBP) on the control of HMB and quality of life in patients with uterine leiomyoma.

Design: In a double-blind randomized, clinical trial 54 women with uterine leiomyoma were randomly assigned to the intervention/control groups by block randomization.

Setting: Gynecology outpatient clinics. ✓

Intervention: The intervention group received 350 mg of alcoholic extract of *Capsella bursa-pastoris* and the control group received placebo twice daily for three months.

Main outcome measures: Amount of bleeding by Pictorial blood loss assessment chart (PBAC), quality of life by menstrual quality of life questionnaires (MQ) and bleeding duration by calendar were evaluated.

Results: The mean of PBAC decreased from 464.00 ± 283.61 at baseline to 323.82 ± 207.66 in the intervention group and decreased from 445.92 ± 362.64 to 214.36 ± 137.68 in control group in the third month. The improvement trend was significant in the two groups, but there was no significant difference between groups. The mean of bleeding duration and menstrual quality of life showed improvement in patients of two groups without significant difference between the two groups.

Conclusion: Despite the effectiveness of CBP in the intervention group in decreasing of PBAC score and menstrual bleeding duration and improvement of menstrual quality of life in patients

who suffered from UL, it did not show a significant effect compared to the control group. Future studies with a larger sample size in one specific type of UL suggested.

Keywords: *Capsella bursa-pastoris*, leiomyoma, quality of life, uterine, Heavy Menstrual Bleeding.

Introduction:

Leiomyoma is smooth muscle tumours that occur in various parts of the body with soft tissues and most frequently occur in the uterus. The estimated prevalence of uterine leiomyoma by age 50 is nearly 70% -80% ¹⁻³. Approximately, one third to half of the women over 35 have UL (fibroids) and 25% of women in reproductive age affected to uterine tumours and was considered as one of spontaneous abortion causes ⁴. According to the reports, UL is responsible for 33% of hysterectomies annually in the United States ⁵. Prolonged menstruation and irregular bleeding (spotting) between periods are the prevalent symptoms of leiomyoma in addition to Heavy Menstrual Bleeding (HMB) ^{5,6}. HMB is the most significant symptom of leiomyoma, often occurs in one-third of the symptomatic patients, and generally reflects the need for treatment ⁵. The complication of HMB is anaemia and as a result, pallor, fatigue, palpitations, boredom, and depression affected on individual and social performance and is a life-threatening problem ^{5,7}. Moreover, HMB in patients with uterine leiomyoma is one of the critical health problems and one of the most crucial indications of hysterectomy. Several surgical and non-surgical therapies include laparotomy, laparoscopy, or hysteroscopy myomectomy, uterine artery embolization and medicinal treatments ^{1,4,8}. Although non-steroidal anti-inflammatory drugs are more effective than placebo in functional uterine bleeding, there is no clinical evidence in favour of their positive impact on leiomyoma-related bleeding ^{4,5}. However, the oral medications including anti-fibrinolytic drugs (e.g., tranexamic acid), hormonal contraceptives, GnRH agonists, selective progesterone receptor modulators, aromatase inhibitors, and estrogen receptor antagonists, are effective on leiomyoma-related bleeding, but have specific complications or contraindication ^{6,7,9}.

Numerous studies are already underway to investigate new medications, and a part of these studies focuses on plants and their extracted compounds ^{4,9-16}. *Capsella bursa-pastoris* (L.)

Medik. (Brassicaceae) commonly known as 'shepherd's purse' is an edible plant with young leaves and roots that are eaten raw or cooked in Asian and European countries^{17, 18}. This plant is one of the herbs traditionally used to control different types of bleeding, particularly uterine bleeding, in many cultures^{13, 19-23}. *CBP* was referred to as "blood plant" in the middle ages and used to control bleeding anywhere in the body either orally (extract and decoction) or topically²⁴. The aerial parts of *CBP* contain phenolic compounds, amino acids, fatty acids, organic acids, phytosterols, tyramine, and choline²⁵. The phenolic compounds, including flavonoids, and alkaloids are responsible for the anti-inflammatory, analgesic, anti-fever, and anti-cancer effects in *CBP*. Today, *CBP* is known as an uterotrophic and hemostatic composition^{26,27}. The impact of the alcohol extract of the *CBP* on the control of leiomyoma-related uterine bleeding is not demonstrated, but its anti-haemorrhage effect showed in several studies^{21,25}. Due to lack of information on the impact of *CBP* on controlling the uterine bleeding in UL, this study aimed to assess the effect of the alcohol extract of this functional food on the control of HMB and quality of life in patients with uterine leiomyoma.

Materials and Methods:

Study design and participants

This study was a double-blind randomized, placebo-controlled clinical trial that conducted in outpatient clinics of Qom University of Medical Sciences from February 2018 to January 2019. It was approved by the ethics committee of Qom University of Medical Science (ethical code: IR.MUQ.REC.1396.110) and registered at Iranian registry clinical Trials centre (No IRCT20161226031582N1).

Inclusion criteria consisted of women within the age range of 18 to 45 years, menstrual bleeding with a score more than 100 in Pictorial Blood Assessment chart (PBAC), uterine leiomyoma proven by ultrasound, not use of any effective medication on menstrual bleeding (OCP, ASA, anti-coagulant), not regular herbal using during the 2 weeks before the study, no abnormal pap smear, no pregnancy, no breastfeeding and absence of systemic disease (thyroid, hyperprolactinemia, coagulopathy, hemoglobinopathy). Exclusion criteria were surgical indications including abnormal bleeding that led to haemodynamic instability, acute pain, severe urinary symptoms or hydronephrosis and Unwillingness to continue treatment.

The minimum sample size for this study calculated based on the power 80%, confidence interval 95%, and the acceptable precision. Based on the results of Naafe et al study, (mean

difference=5.3, SD for each group=6), the minimum sample size for each group was estimated as 22 patients²¹.

Randomization

The block random allocation method used to assign the eligible patients to the study groups. The size of block considered 4. Therefore, six quadruple blocks created. Selection of each block was a crash and done using dice throwing. Enrolment of eligible patients was based on convenience methods after a description of study purpose to each patient and signing the informed consent form. Each patient received a code at the beginning of the study and was placed in either A or B group.

Preparation of drug and placebo

The aerial part of *Capsella bursa pastoris* (L.) Medik. was collected from the areas around Khansar City (Isfahan Province) in June 2017. In the botanical lab of the School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, with herbarium code SBMU-1054 was identified. According to previous studies, this plant is safe and LD50 values are more than 3000 mg/kg²⁸. For preparing the drug, *C. bursa-pastoris* plants were soaked at room temperature with 96% alcohol for 3 consecutive nights (X 3) and thus extracted. After evaporation of alcohol, dry powder of plant prepared and mixed with starch and packed in capsules of size 0, made by Iran Gelatin capsule company. Each capsule has 350 mg extract (from 7 gram of plant) and 150 mg starch. The average therapeutic dose of *CBP* for internally use is 10-15 grams dry plant per day^{21,29}. The extract of *CBP* was analyzed for the total Phenolic, flavonoid, and tannin content, respectively by the Folin–Ciocalteu colorimetric method, aluminium trichloride method, and titrimetric indigosulphonic acid assay³⁰⁻³³.

The placebo capsule filled with the 150 mg of starch. The drug and placebo capsules were similar in shape and size and were given to participants twice a day. The prepared capsules were delivered to the researcher in sealed packages coded with A and B. The A or B code for the drug and placebo was randomly selected.

Measurements

Abnormal uterine bleeding was assessed by Pictorial blood assessment chart (PBAC). PBAC is a chart that works by recording a count for each type of sanitary pad used and its degree of soaking that depicted in a pictorial table along with the count and size of blood clots. The scores of full

filled, half-filled, and less than half-filled sanitary pad are 20, 5 and 1, respectively. In addition, the score of a small blood clot and large blood clot are 5 and 1, respectively. Finally, the scores are summed and one score calculate for each patient. If the score is more than 100, it indicates uterine bleeding is more than 80 cc. The accuracy of this test has been reported differently in different studies but is still the most applicable method for measuring the amount of menstrual blood loss ³⁴. In addition, the Persian version of the Menorrhagia Questionnaire (MQ) was used to assess the quality of life. The total score of MQ varied from zero to 100 and a lower score means a better quality of life. The validity and reliability of this questionnaire have been confirmed in other studies in Iran ^{35,36}.

Intervention

Before the study, the patient evaluated for participation in the intervention. First, PBAC chart was given to them for assessment the amount of bleeding for baseline. This chart was given to them three-time else during the study, at first, second and third month after the intervention. Before and after of treatment, vaginal and abdominal ultrasound were performed according to the patient's condition and the size of the leiomyoma under the supervision of a specialist in the infertility centre of Forghani Hospital in Qom. Before the intervention, pelvic exam also was performed for the Married participants. Laboratory tests including TSH, PT, PTT, Hb, Plt was measured in the laboratory of Forghani hospital before study to rule out other causes of bleeding. After delivery of the first PBAC form by the patient, two capsules were prescribed per patient code (A or B) daily for three months. Patients were advised to take capsules at 10 AM and 5 PM for better absorption with a glass of water. In this study, that was double-blind, both patients and researchers were unaware of the particular drug-assigned to each patient. All patients in two studied groups were given iron supplementation, due to ethical considerations. MQ form completed two times by the patient once at baseline and again at the end of the study after the intervention.

Statistical Analysis

Data included PBAC scores, MQ scores, number of bleeding days, ultrasound results, laboratory test results, and other collected data analyzed by SPSS software (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.). Intention to treatment

method was used for comparing data between two groups. Normality of data checked by histogram and Shapiro-wilk test. Descriptive statistics including mean and percent frequency was used for descriptive data. Chi-square and t-test used to compare the studied variables in the intervention and control groups. Moreover, the analysis of variance for repeated measures was used to assess the within and between trend of bleeding in two groups.

Result:

Phytochemical analysis results

Total phenolic and flavonoid contents of the *CBP* alcoholic extract were 29 mg GAE /g powder and 19.6 mg rutin/g powder, respectively. The percentage of tannin in terms of Gallic acid in the *CBP* plant was 4.57%.

Clinical trial results

140 women with heavy menstrual bleeding and uterine leiomyoma were evaluated for their eligibility to study. 81 patients did not meet the inclusion criteria, 4 of them did not accept to participate and one of them did not follow the next steps. Finally, 54 eligible patients were randomized in two groups, intervention (n=27) and placebo (n=27). In the first month of study, three patients in intervention group were excluded because lack of control of heavy bleeding and one in placebo group was excluded for unwillingness to continue the intervention. In the second month, one patient in intervention group was excluded because of she of pregnancy. In the third month, one patient in intervention group was excluded due to failure to deliver the form of bleeding and one in placebo group because of consumption of another herbal medicine with the drug. Finally, the results of the study were analyzed with 47 subjects, 22 patients in intervention group and 25 ones in placebo group. (Fig 1) After completing the study, the nature of the drug samples were disclosed by the pharmacologist.

The baseline demographic characteristics (table1) including age, level of education, marital status, body mass index, and blood pressure were analyzed. Two group are homogenous in BMI 28.4 ± 5.75 vs. 30.74 ± 5.23 ($p=0.151$), systolic BP 112.01 ± 12.66 Vs. 118.15 ± 15.24 ($p= 0.136$), diastolic BP 76.2 ± 8.86 vs. 76.59 ± 10.84 ($p=0.41$) and age 41.27 ± 3.15 vs. 40.0 ± 4.70 ($p=0.277$). Moreover, two groups were same regarding to the educational level ($p=0.396$) and marital status ($p=0.230$).

The mean of baseline bleeding based on PBAC score in intervention and control group was 464.00 ± 283.61 and 445.92 ± 362.64 , respectively and their difference was not statistically significant ($p=0.851$). The independent t-test (table 2) also did not show significant difference

between two groups one month after treatment ($p=0.160$). Nevertheless, a significant difference was shown in PBAC score after the second ($p=0.017$) and third month ($p=0.037$) of treatment. The analysis of variance for repeated measurement (figure 2) showed that there was a significant decreasing trend in PBAC score in two groups ($p<0.001$), but the improvement trend was not statistically different between two groups ($p=0.115$).

The independent t-test showed that the mean of bleeding duration (table 3) was not statistically significant between two groups at baseline and each month during the intervention ($p>0.05$). Nevertheless, analysis of variance for repeated measurement showed that there was a significant decreasing trend (Figure 3) in bleeding duration in intervention and control groups ($p=0.001$). However, there was no significant difference between two groups ($p=0.308$).

In the present study, the menstrual quality of life was the same in two groups (55.44 ± 11.96 vs 47.79 ± 16.81) at baseline ($p=0.083$) and it is not different between groups (44.84 ± 16.02 vs 37.71 ± 18.31) after the intervention ($p=0.165$). However, the improvement of quality of life was observed in two study groups ($p<0.001$).

In the ultrasound, before and after the study, the number, size, and type of each leiomyoma were recorded. The mean number of leiomyoma in the intervention and control groups was 1.67 ± 0.945 and 1.72 ± 0.890 , respectively. Based on paired t-test, there was no significant difference in the number of leiomyoma between the two groups before and after the study. T-test also did not show a significant difference in the size of leiomyoma between two groups before and after the study. Moreover, the size of the leiomyoma did not show any significant change after treatment and was not significant between the two groups ($p>0.05$). The most common typical types of leiomyoma were intramural, subserosal and submucosal, respectively.

Side effects

There was no significant difference between two groups regarding to side effects. ($p>0.05$). In the intervention group, 18.2% (4 patients), and in the placebo group 16% (4 patients), were reported side effects. The complications in the intervention group including hemorrhoid (9.1%), constipation (4%), Skin dryness (4%), and pelvic cramps (4%). The complications in control group including stomach ache, headache, hair loss, and acne.

Discussion:

The current study was the first randomized clinical trial on the effect of *CBP* in heavy menstrual bleeding due to UL. Our results showed a significant improvement trend in PBAC score in all studied patients in two groups and there was no significant difference between intervention and control groups. However, the mean of uterine bleeding decreased in the intervention group from 464.00 ± 283.61 at baseline to 323.82 ± 207.66 in the third month after treatment with *CBP*. Moreover, the mean of bleeding decreased from 445.92 ± 362.64 to 214.36 ± 137.68 after follow up in control group. Other studies showed that the extract of *CBP* is an effective drug on control of non-structural heavy menstrual bleeding and postpartum haemorrhage ^{21,22}(1,2). Our results also showed a decrease in duration of bleeding but there was not the difference between *CBP* and control group. The mean of days with bleeding decrease from 10.32 ± 5.60 to 8.91 ± 2.99 in intervention group and decreased from 9.80 ± 6.23 to 7.80 ± 2.39 in control group.

Although *CBP* has been effective in reducing bleeding in this study, other studies on the effect of this plant on unrelated leiomyoma uterine bleeding have reported better results. The study was conducted in Iran by Naafe et al., on the effect of *CBP* on non-structural uterine bleeding showed a reduction in the amount of menstrual bleeding by the hydroalcoholic extract of *CBP*. This reduction was more significant in the *CBP* group, compared to the control group ²¹. Another study was conducted by Ghalandari et al., demonstrated that the amount of postpartum bleeding was lower in the *CBP* and oxytocin group first, second, and third hours after the delivery, compared to the oxytocin group ²². The chemical composition and biological effect of *CBP* is responsible for the control of bleeding. Some studies assume that its contractile nature of *CBP* is due to the presence of oxytocin-like polypeptides ³⁷. *CBP* is rich in phenolic and flavonoid compounds that show the antioxidant, anti-inflammatory and antibacterial effects of this plant ^{11, 24, 25}. In the past, tyramine and choline were responsible for controlling the bleeding by the plant. Today's, new researches have shown that other substances that are not fully recognized may be responsible for such an effect ²⁵⁻³⁸. Anyway, the contractile and hemostatic nature of this drug **cannot be ignored**. **Different** response to treatment in this study may be due to the mechanism of uterine bleeding in leiomyoma like widening of endometrial veins, vascular weakness, and abnormal contractions of the uterus and leiomyoma superficial vascular bed. Moreover, **haemeostatic problems** due to abnormal angiogenesis **caused a synergistic effect on heavy** bleeding ^{1,39}.

Due to the inflammatory environment surrounding leiomyoma, any anti-inflammatory agent, including flavonoids, can be effective in controlling the complications of these tumors. Perhaps the higher amount of this substance in the plant will be more effective in controlling inflammation

and symptoms in the leiomyoma. A study conducted by Memarzadeh et al., showed that Persian Gulnar significantly reduced leiomyoma related uterine bleeding. In that study, the flavonoid content of Gulnar was much higher than the current study. Therefore, Gulnar has been more effective than *CBP* in controlling leiomyoma symptoms⁴⁰. Control of inflammation is only one of the mechanisms of control of hemorrhage in patients with leiomyoma. In herbal studies on control of uterine bleeding, Tannins have an astringent property and can cause contraction of uterine vessels that leads to decreased exudation and blood loss^{32, 36, 40, 41}. Compared to some materials such as pomegranate peel and oak, tannin content of *CBP* is relatively low^{30, 42, 43}.

The anatomical position, number, and size of the uterine leiomyomas are effective factors of the volume of bleeding in patients with UL that caused excessive uterine bleeding as well as prolonged menstrual period^{1, 6, 44}.

The ultrasound showed both groups were similar in number and size of the leiomyomas before the study. The mean number and size of the leiomyoma did not change significantly after the study in both groups. Stewart's study, which was based on the effect of two doses of asoprisnil (10 or 25 mg) on uterine bleeding with leiomyoma, after 6 months, showed reduction in size of uterine leiomyoma up to 45% with asoprisnil 10 mg and 54% with asoprisnil 25 mg versus increase in size of uterine leiomyoma up to 44% with placebo⁷. Contrary to Stewart's study in the current study, no increase in leiomyoma size observed. Short duration of our study or *CBP* effect may be responsible for such a result.

The most common typical location of leiomyoma in our study was intramural, subserosal and submucosal respectively like other studies such Memarzadeh⁴⁰.

Based on the recent studies, UL is a significant related factor in decreasing the quality of life in women of reproductive age¹. Improvement in mean scores of menstrual quality of life was same in our and Memarzadeh study. ($p < 0.001$)⁴⁰. In the study by Naafe, the patient's satisfaction rate was significantly higher in the *CBP* group compare to control group²¹. These results also point to a better performance of *CBP* in reducing non-structural uterine bleeding over structural causes.

The most side effects in the intervention group were hemorrhoid, constipation, skin dryness, and pelvic cramps. This plant is anti-diarrhea in folklore medicine so constipation was because of the astringent nature of the plant²⁴. Hemorrhoid may be due to constipation. Pelvic cramps are also due to contractions was created by the plant³⁷. Stomachache, hair loss, headache, and acne were the most complications in patients of the intervention group. These complications seem to be more due to blood loss.

The present study assessed the extract effect of *CBP* on heavy menstrual bleeding and quality of life in patients suffering from uterine leiomyoma for the first time in a pilot study.

Mechanisms of bleeding are different in leiomyoma as structural uterine problems with nonstructural disorders so more studies must have conducted to compare the effect of *CBP* on bleeding due to structural and nonstructural uterine disorders. It also recommended studying the possible effects of starch on uterine bleeding and leiomyoma.

Conclusion:

The *CBP* caused an improvement trend in PBAC score of patients who suffered from UL and decrease the menstrual bleeding duration. Moreover, the menstrual quality of life showed an improvement trend. however, there was no clinically significant difference between intervention and control groups regarding to PBAC score, bleeding duration and quality of life.

Limitation:

Small sample size and variety in types of UL were the limitations of this study. Therefore, future studies with larger sample size in one specific type of UL suggested.

References:

1. de la Cruz MSD, Buchanan EM. Uterine fibroids: Diagnosis and treatment. *Am Fam Physician*. 2017;95(2):100–7.
2. Ehman EC, Johnson GB, Villanueva-meyer JE, Cha S, Leynes AP, Eric P, et al. Epidemiology of Uterine Fibroids – From Menarche to Menopause. *Clin Obs Gynecol*. 2017;46(5):1247–62. doi:10.1097/GRF.0000000000000164.
3. Berek JS. *Berek & Novak's Gynecology*. 16th ed. Berek JS, editor. Vol. 1, Wolters Kluwer.

Philadelphia: Wolters Kluwer; 2020. 213.

4. Chwalisz K, Taylor H. Current and emerging medical treatments for uterine fibroids. In: *Seminars in reproductive medicine*. Thieme Medical Publishers; 2017. 510–22. doi: [10.1055/s-0037-1606302](https://doi.org/10.1055/s-0037-1606302).
5. Jones HWI, Rock JA. *Textbook of gynecology*. 11th ed. Philadelphia: Wolters Kluwer; 2016. 1160–1193.
6. Hoffman BL, Schorge JO, Bradshaw KD, Halvorson LM, Schaffer JI, Corton MM. *Williams Gynecology*. third. McGraw-Hill Education; 2016. 202–212.
7. Stewart EA, Diamond MP, Williams ARW, Carr BR, Myers ER, Feldman RA, et al. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. *Hum Reprod*. 2019;1–12. doi:10.1093/humrep/dez007.
8. Marnach ML, Laughlin-Tommaso SK. Evaluation and Management of Abnormal Uterine Bleeding. *Mayo Clin Proc* [Internet]. 2019;94(2):326–35. <https://doi.org/10.1016/j.mayocp.2018.12.012>
9. Islam MS, Protic O, Giannubilo SR, Toti P, Tranquilli AL, Petraglia F, et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. *J Clin Endocrinol Metab*. 2013;98(3):921–34. <https://doi.org/10.1210/jc.2012-3237>.
10. Lewis TD, Malik M, Britten J, San Pablo AMA, Catherino WH. A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma. *BioMed Research International*. 2018. <https://doi.org/10.1155/2018/2414609>.

11. Masullo M, Montoro P, Mari A, Pizza C, Piacente S. Medicinal plants in the treatment of women's disorders: Analytical strategies to assure quality, safety and efficacy. *J Pharm Biomed Anal* [Internet]. 2015;113:189–211. Available from: <http://dx.doi.org/10.1016/j.jpba.2015.03.020>
12. Akhtar MM, Ciavattini A, Giannubilo SR, Protic O, Janjusevic M, Procopio AD, et al. Use of dietary phytochemicals to target inflammation , fibrosis , proliferation , and angiogenesis in uterine tissues : Promising options for prevention and treatment of uterine fibroids ? 2014;1667–84. <https://doi.org/10.1002/mnfr.201400134>.
13. Tetik F, Civelek S, Cakilcioglu U. Traditional uses of some medicinal plants in Malatya (Turkey). *J Ethnopharmacol.* 2013;146(1):331–46. <https://doi.org/10.1016/j.jep.2012.12.054>.
14. Hosseini SE. Report of Health Care Therapeutic Effects of Medicinal Herbs on Reproductive System Disorders : A Review. 2018;4(3):67–76.
15. Eshaghian R, Mazaheri M, Ghanadian M, Rouholamin S, Feizi A, Babaeian M. The effect of frankincense (*Boswellia serrata*, oleoresin) and ginger (*Zingiber officinale*, rhizoma) on heavy menstrual bleeding: A randomized, placebo-controlled, clinical trial. *Complement Ther Med* [Internet]. 2019;42:42–7. <https://doi.org/10.1016/j.ctim.2018.09.022>.
16. Nasiri M, Gheibi Z, Miri A, Rahmani J, Asadi M, Sadeghi O, et al. Effects of consuming date fruits (*Phoenix dactylifera* Linn) on gestation, labor, and delivery: An updated systematic review and meta-analysis of clinical trials. *Complement Ther Med* [Internet]. 2019; 74: 71-84. <https://doi.org/10.1016/j.ctim.2019.05.017>
17. Choi WJ, Kim SK, Park HK, Sohn UD, Kim W. Anti-inflammatory and anti-superbacterial

properties of sulforaphane from shepherd's purse. *Korean J Physiol Pharmacol.* 2014;18(1):33–9. <https://doi.org/10.4196/kjpp.2014.18.1.33>.

18. Hur J, Yoo M, Shin D bin, Lee S. Inhibition of nitric oxide production corresponds to the sulforaphane content in Korean sheperd's purse (*Capsella bursa-pastoris*) and related species in BV-2 cell. *Food Sci Biotechnol.* 2013;22(4):1085–9.
19. Miraldi E, Ferri S, Mostaghimi V. Botanical drugs and preparations in the traditional medicine of West Azerbaijan (Iran). *J Ethnopharmacol.* 2001;75(2–3):77–87. [https://doi.org/10.1016/S0378-8741\(00\)00381-0](https://doi.org/10.1016/S0378-8741(00)00381-0).
20. Güler B, Kümüştekin G, Uşurlu E. Contribution to the traditional uses of medicinal plants of Turgutlu (Manisa - Turkey). Vol. 176, *Journal of Ethnopharmacology.* 2015. 102–8. <https://doi.org/10.1016/j.jep.2015.10.023>.
21. Naafe M, Kariman N, Keshavarz Z, Khademi N, Mojab F, Mohammadbeigi A. The Effect of Hydroalcoholic Extracts of *Capsella Bursa-Pastoris* on Heavy Menstrual Bleeding: A Randomized Clinical Trial. *J Altern Complement Med.* 2018;24(7):694–700. <https://doi.org/10.1089/acm.2017.0267>.
22. Ghalandari S, Kariman N, Sheikhan Z, Mojab F, Mirzaei M, Shahrahmani H. Effect of Hydroalcoholic Extract of *Capsella bursa pastoris* on Early Postpartum Hemorrhage: A Clinical Trial Study. *J Altern Complement Med.* 2017;23(10):794–9. <https://doi.org/10.1089/acm.2017.0095>.
23. Sehhati F, Mirghafourvand M, Hamzehpour R. The comparative effect of *capsella bursa-pastoris* and mefenamic acid on sexual function of copper IUD users. *Int J Women's Heal Reprod Sci [Internet].* 2018;6(2):192–8. <http://dx.doi.org/10.15296/ijwhr.2018.32>.

24. Defelice MS. Shepherd's-purse, *Capsella bursa-pastoris* (L.) Medic. *Weed Technol.* 2002;16(4):901–7. [https://doi.org/10.1614/0890-037X\(2001\)015\[0892:SSPCBP\]2.0.CO;2](https://doi.org/10.1614/0890-037X(2001)015[0892:SSPCBP]2.0.CO;2).
25. Grosso C, Vinhole J, Gonçalves RFR, Valentão P, Jäger AAK, Andrade PPB, et al. Chemical composition and biological screening of *Capsella bursa-pastoris*. *Rev Bras Farmacogn Brazilian J Pharmacogn.* 2011;21(4):635–44. <http://dx.doi.org/10.1590/S0102-695X2011005000107>.
26. Lans C, Turner N, Khan T, Brauer G, Boepple W. Ethnoveterinary medicines used for ruminants in British Columbia, Canada. *J Ethnobiol Ethnomed.* 2007;3:1–22. <https://doi.org/10.1186/1746-4269-3-11>.
27. Khare CP. *Indian medicinal plants.* Springer. New Dehli: Springer; 2017. 119.
28. Lan X, Qing-Hu W, Bai-yin-mu-qi-er W, A-gu-la1 B. Chemical composition and anti-inflammatory effects of the EtOAc extract from *Capsella bursa-pastoris* (L.) Medic. *African J Pharm Pharmacol.* 2017;11:186–90.
29. Gruenwald J, Brendler T, Jaenicke C. *PDR for herbal Medicines.* 2nd ed. Montvale, NJ: Medical Economics Company; 2000. 691.
30. Atanassova M, Christova-Bagdassarian V. Determination of Tannins Content By Titrimetric Method for Comparison of Different Plant Species. *J Univ Chem Technol Metall.* 2009;44(4):413–5. <https://www.researchgate.net/publication/257076247>
31. Rebaya A, Belghith SI, Baghdikian B, Leddet VM, Mabrouki F, Olivier E, et al. Total Phenolic, Total Flavonoid, Tannin Content, and Antioxidant Capacity of *Halimium halimifolium* (Cistaceae). *J Appl Pharm Sci.* 2015;5(1):052–7. doi: 10.7324/JAPS.2015.50110

32. Shafiee M, Heidari A, Amouzegar H, Khani S, Nojavan F. "Evaluation of the effect of roasted lentil flour (lentil savigh) as a functional food in menstrual bleeding reduction." *Complement Ther Med.* 2019;44(December 2018):27–31. <https://doi.org/10.1016/j.ctim.2019.03.010>.
33. Bryan-thomas J. A Comparative Study of the Antioxidant Activity (DPPH), Total Flavonoid, Total Tannin, Total Polyphenol Levels in Plant Extracts of the *Annona muricata*, *Ribes nigrum* and *Manilkara zapota*. *Int J Sci Res Publ.* 2016;6(9):490–4.
34. El-Nashar SA, Shazly SAM, Famuyide AO. Pictorial blood loss assessment chart for quantification of menstrual blood loss: a systematic review. *Gynecol Surg.* 2015;12(3):157–63.
35. Mazari Z, Goshtasebi A, Mookhah S, Saki F. The menorrhagia questionnaire (MQ): translation and validation study of the Iranian version. *PAYESH.* 2012;11(1):83–5.
36. Qaraaty M, Kamali SH, Dabaghian FH, Zafarghandi N, Mokaberinejad R, Mobli M, et al. Effect of myrtle fruit syrup on abnormal uterine bleeding: A randomized double-blind, placebo-controlled pilot study. *DARU, J Pharm Sci.* 2014;22(1):45. <https://doi.org/10.1186/2008-2231-22-45>.
37. Al-snafi AE. Medicinal plants affected contractility of smooth muscles- A review. 2018;8(11):22–35.
38. Kuroda K, Takagi K. Physiologically active substance in *Capsella bursa-pastoris*. *Nature.* 1968;220(5168):707–8.
39. Ikhen DE, Bulun SE. Literature Review on the Role of Uterine Fibroids in Endometrial Function. Vol. 25, *Reproductive Sciences.* 2018. 635–43.

40. Memarzadeh H, Eftekhari T, Tansaz M, Hashem Dabaghian F, Kamalinejad M. Evaluation of efficacy of *Punica granatum* L. (Persian gulnar) on uterine leiomyoma related menorrhagia: a pilot study. *Int J Biosci.* 2015;6(9):18–25.
41. Bahman M, Mirahi A, Hajimehdipour H, Tansaz M. The effect of quince paste on menorrhagia: a clinical study. *Int J Pharm Sci Res.* 2017;9(4):1654–9. doi: 10.13040/IJPSR.0975-8232.9(4).1654-59.
42. Russo M, Fanali C, Tripodo G, Dugo P, Muleo R, Dugo L, et al. Analysis of phenolic compounds in different parts of pomegranate (*Punica granatum*) fruit by HPLC-PDA-ESI/MS and evaluation of their antioxidant activity: application to different Italian varieties. *Anal Bioanal Chem.* 2018;410(15):3507–20.
43. Nabavizadeh MR, Zargaran A, Moazami F, Askari F, Sahebi S, Farhadpoor A, et al. Comparison of the Hemostatic Activity of *Quercus persica* Jaub. & Spach. (Oak) With Ferric Sulfate in Bony Crypts. *J Evidence-Based Complement Altern Med.* 2016;21: 34-38. <https://doi.org/10.1177/2156587215593378>.
44. Donnez J, Dolmans MM. Uterine fibroid management: From the present to the future. *Hum Reprod Update.* 2016;22(6):665–86. <https://doi.org/10.1093/humupd/dmw023>.

Table 1: Comparison the baseline demographic and blood pressure of two studied groups

Characteristic	CBP group (n=22)	Control group (n=25)	P- value
Age	40.0±4.70	41.27±3.15	0.277*
BMI	30.74±5.23	28.4±5.75	0.151*

Systolic BP		118.15±15.24	112.01±12.66	0.136*
Diastolic BP		76.59±10.84	76.2±8.86	0.410*
Marital Status	Single	7(28%)	3 (13.6%)	0.230**
	Married	18(72%)	19(86.4%)	
Education	Lower diploma	8(32%)	8(36.4%)	0.396**
	Diploma	8(32%)	9(40.9%)	
	Bachelor and higher	9(36%)	5(22.7%)	

*t-test

**Chi square test

Table 2. Comparison of PBAC scores before and after treatment.

PBAC score	CBP group(n=22)		Control group (n=25)		P value*
	Mean	SD	Mean	SD	
Baseline	464.00	283.61	445.92	362.64	0.851
After first month	372.64	225.63	261.36	297.29	0.160
After second month	357.59	242.71	215.40	145.10	0.017
After third month	323.82	207.66	214.36	137.68	0.037
P value**	<0.001		<0.001		

*T-test

** Analysis of variance for repeated measurement

Table 3: Comparison of duration of bleeding before and after treatment

Duration of bleeding	CBP (n=22)	Control group (n=25)	P value*
----------------------	------------	----------------------	----------

	Mean	SD	Mean	SD	
Baseline	10.32	5.60	9.80	6.23	0.767
After first month	8.50	2.54	8.32	2.88	0.822
After second month	8.54	3.66	7.00	2.96	0.117
After third month	8.91	2.99	7.80	2.39	0.165
P value**	<0.001		0.001		

*T-test

** Analysis of variance for repeated measurement




Figure 1. The CONSORT diagram